CA
NZ
UK
AU
IND
US
Liquidia (NASDAQ:LQDA) announced after the close on October 13 a global settlement with United Therapeutics resolving all pending litigation, including six lawsuits and antitrust claims, and securing continued commercialization of Yutrepia for pulmonary arterial hypertension. The company will pay United Therapeutics USD 175 million …
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant recent context. Olema (NASDAQ:OLMA) reported August 10 that enrollment in its pivotal Phase 3 OPERA-01 trial of palazestrant, in second- and …
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant available context. Omada Health (NASDAQ:OMDA) provides virtual chronic care programs for conditions such as diabetes and hypertension, and it rose 3.83% …
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant available context. Picard Medical (NYSEAMERICAN:PMI), parent of SynCardia Systems and its FDA and Health Canada approved Total Artificial Heart, fell 7.31% …
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant available context. Scienture Holdings (NASDAQ:SCNX), a small specialty pharmaceutical company, rose 12.35% to USD 3.24 pre-market on 2,640 shares, and the …
Alaunos Therapeutics (NASDAQ:TCRT) announced October 13 it completed the acquisition of Velaris Therapeutics, a privately held company developing therapies for pulmonary arterial hypertension and related cardiopulmonary diseases, alongside an oversubscribed private placement of about USD 350 million. The placement of Series C non-voting convertible …
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant available context. Wave Life Sciences (NASDAQ:WVE), an RNA medicines company, rose 7.95% pre-market to USD 3.14 on 4,100 shares, with an …
UnitedHealth Group (NYSE:UNH) reported third-quarter EPS of USD 4.69 on October 13, 2026, against a consensus of USD 4.06, and raised its 2026 EPS guidance to at least USD 20.50. The beat of USD 0.63 a share is about 15.5% above the estimate, simple …
Roche Holding (OTCQX:RHHBY) agreed to licence an obesity drug from Rona Therapeutics, paying USD 100 million upfront with the potential for up to USD 1.06 billion more in milestone payments, according to reports dated October 13, 2026. Simple arithmetic puts the total potential value …
Roche Holding (OTCQX:RHHBY) agreed to licence an obesity drug from Rona Therapeutics, paying USD 100 million upfront with the potential for up to USD 1.06 billion more in milestone payments, according to reports dated October 13, 2026. Simple arithmetic puts the total potential value …
Please wait processing your request...